Current status of basic and clinical research on metformin in endometrial cancer

doi:10.3760/cma.j.cn371439-20200208-00053

Abstract

Abstract:

Endometrial cancer is one of the most common gynecological malignancies, which is closely related to metabolic syndrome such as diabetes mellitus. In recent years, epidemiological studies have found that metformin has a positive effect on the prevention and treatment of endometrial cancer, and a large number of basic and clinical studies have supported this theory, indicating that metformin may become the new treatment for patients with endometrial cancer, especially with advanced and recurrent endometrial cancer, and endometrial dysplasia.

Key words: Endometrial neoplasms, Metformin, Diabetes mellitus, Insulin resistance

Zhao Xiaoling, Kong Weimin. Current status of basic and clinical research on metformin in endometrial cancer[J]. Journal of International Oncology, 2020, 47(7): 440-443.

References 26

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. pmid: 30207593
[2]	Moore K, Brewer MA. Endometrial cancer: is this a new disease?[J]. Am Soc Clin Oncol Educ Book, 2017,37:435-442. DOI: 10.1200/EDBK_175666. pmid: 28561715
[3]	Gonthier C, Trefoux-Bourdet A, Luton D, et al. Fertility-sparing management of endometrial cancer and atypical hyperplasia[J]. Gynecol Obstet Fertil Senol, 2017,45(2):112-118. DOI: 10.1016/j.gofs.2016.12.011. pmid: 28368791
[4]	Lee TY, Martinez-Outschoorn UE, Schilder RJ, et al. Metformin as a therapeutic target in endometrial cancers[J]. Front Oncol, 2018,8:341. DOI: 10.3389/fonc.2018.00341. doi: 10.3389/fonc.2018.00341 pmid: 30211120
[5]	Chu D, Wu J, Wang K, et al. Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis[J]. BMC Cancer, 2018,18(1):438. DOI: 10.1186/s12885-018-4334-5. pmid: 29669520
[6]	Meireles CG, Pereira SA, Valadares LP, et al. Effects of metformin on endometrial cancer: systematic review and meta-analysis[J]. Gynecol Oncol, 2017,147(1):167-180. DOI: 10.1016/j.ygyno.2017.07.120. doi: 10.1016/j.ygyno.2017.07.120 pmid: 28760367
[7]	Morales DR, Morris AD. Metformin in cancer treatment and prevention[J]. Annu Rev Med, 2015,66:17-29. DOI: 10.1146/annurev-med-062613-093128. doi: 10.1146/annurev-med-062613-093128 pmid: 25386929
[8]	Tian W, Teng F, Zhao J, et al. Estrogen and insulin synergistically promote type 1 endometrial cancer progression[J]. Cancer Biol Ther, 2017,18(12):1000-1010. DOI: 10.1080/15384047.2017.1394547. doi: 10.1080/15384047.2017.1394547 pmid: 29172956
[9]	Collins G, Mesiano S, DiFeo A. Effects of metformin on cellular proliferation and steroid hormone receptors in patient-derived, low-grade endometrial cancer cell lines[J]. Reprod Sci, 2018,1:1933719118779734. DOI: 10.1177/1933719118779734.
[10]	Zhang J, Xu H, Zhou X, et al. Role of metformin in inhibiting estrogen-induced proliferation and regulating ERα and ERβ expression in human endometrial cancer cells[J]. Oncol Lett, 2017,14(4):4949-4956. DOI: 10.3892/ol.2017.6877. doi: 10.3892/ol.2017.6877 pmid: 29085506
[11]	Zhang HH, Guo XL. Combinational strategies of metformin and chemotherapy in cancers[J]. Cancer Chemother Pharmacol, 2016,78(1):13-26. DOI: 10.1007/s00280-016-3037-3. doi: 10.1007/s00280-016-3037-3 pmid: 27118574
[12]	Wallbillich JJ, Josyula S, Saini U, et al. High glucose-mediated STAT3 activation in endometrial cancer is inhibited by metformin: therapeutic implications for endometrial cancer[J]. PLoS One, 2017,12(1):e0170318. DOI: 10.1371/journal.pone.0170318. pmid: 28114390
[13]	Tabrizi AD, Melli MS, Foroughi M, et al. Antiproliferative effect of metformin on the endometrium-a clinical trial[J]. Asian Pac J Cancer Prev, 2014,15(23):10067-10070. DOI: 10.7314/apjcp.2014.15.23.10067. doi: 10.7314/apjcp.2014.15.23.10067 pmid: 25556427
[14]	Meireles CG, Pereira SA, Valadares LP, et al. Effects of metformin on endometrial cancer: systematic review and meta-analysis[J]. Gynecol Oncol, 2017,147(1):167-180. DOI: 10.1016/j.ygyno.2017.07.120. doi: 10.1016/j.ygyno.2017.07.120 pmid: 28760367
[15]	Davis SR, Robinson PJ, Jane F, et al. The benefits of adding metformin to tamoxifen to protect the endometrium—a randomized placebo-controlled trial[J]. Clin Endocrinol (Oxf), 2018,89(5):605-612. DOI: 10.1111/cen.13830. doi: 10.1111/cen.2018.89.issue-5
[16]	Shafiee MN, Khan G, Ariffin R, et al. Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help[J]. Gynecol Oncol, 2014,132(1):248-253. DOI: 10.1016/j.ygyno.2013.10.028. pmid: 24183733
[17]	Chu D, Wu J, Wang K, et al. Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis[J]. BMC Cancer, 2018,18(1):438. DOI: 10.1186/s12885-018-4334-5. doi: 10.1186/s12885-018-4334-5 pmid: 29669520
[18]	Xie W, Li T, Yang J, et al. Metformin use and survival outcomes in endometrial cancer: a systematic review and meta-analysis[J]. Oncotarget, 2017,8(42):73079-73086. DOI: 10.18632/oncotarget.20388. doi: 10.18632/oncotarget.20388 pmid: 29069850
[19]	Mitsuhashi A, Sato Y, Kiyokawa T, et al. Phase Ⅱ study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer[J]. Ann Oncol, 2016,27(2):262-266. DOI: 10.1093/annonc/mdv539. doi: 10.1093/annonc/mdv539 pmid: 26578736
[20]	Ezewuiro O, Grushko TA, Kocherginsky M, et al. Association of metformin use with outcomes in advanced endometrial cancer treated with chemotherapy[J]. PLoS One, 2016,11(1):e0147145. DOI: 10.1371/journal.pone.0147145. doi: 10.1371/journal.pone.0147145 pmid: 26788855
[21]	Hanna RK, Zhou C, Malloy KM, et al. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway[J]. Gynecol Oncol, 2012,125(2):458-469. DOI: 10.1016/j.ygyno.2012.01.009. doi: 10.1016/j.ygyno.2012.01.009 pmid: 22252099
[22]	王小慧, 张岩, 刘林枝, 等. 二甲双胍与脂联素对子宫内膜癌细胞增殖的作用[J]. 北京大学学报(医学版), 2018,50(5):767-773. DOI: 10.19723/j.issn.1671-167X.2018.05.001.
[23]	Dong L, Zhou Q, Zhang Z, et al. Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase Ⅰ expression[J]. J Obstet Gynaecol Res, 2012,38(8):1077-1085. DOI: 10.1111/j.1447-0756.2011.01839.x. doi: 10.1111/j.1447-0756.2011.01839.x pmid: 22540333
[24]	Bai M, Yang L, Liao H, et al. Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism[J]. Oncogene, 2018,37(42):5666-5681. DOI: 10.1038/s41388-018-0360-7. doi: 10.1038/s41388-018-0360-7 pmid: 29921847
[25]	Xie Y, Wang YL, Yu L, et al. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells[J]. J Steroid Biochem Mol Biol, 2011,126(3-5):113-120. DOI: 10.1016/j.jsbmb.2010.12.006. doi: 10.1016/j.jsbmb.2010.12.006 pmid: 21168492
[26]	Mu N, Dong M, Li L, et al. Synergistic effect of metformin and medroxyprogesterone 17 acetate on the development of endometrial cancer[J]. Oncol Rep, 2018,39(4):2015-2021. DOI: 10.3892/or.2018.6236. doi: 10.3892/or.2018.6236 pmid: 29393479